- Trials with a EudraCT protocol (39)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (4)
39 result(s) found for: Hepatotoxicity.
Displaying page 1 of 2.
| EudraCT Number: 2008-005015-17 | Sponsor Protocol Number: GE09-01 | Start Date*: 2009-05-13 |
| Sponsor Name:VU university medical centre | ||
| Full Title: Effect of N-acetylcysteine on thiopurine related hepatotoxicity in IBD patients | ||
| Medical condition: adult patients (18-70 years old) who have been treated with azathioprine, 6-mercaptopure or 6-thioguanine for inflammatory bowel disease, in whom hepatotoxicity occured as an adverse event, are eli... | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: NL (Ongoing) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2009-015403-95 | Sponsor Protocol Number: NS10364-3 | Start Date*: 2010-02-11 |
| Sponsor Name:Faculty Hospital Hradec Králové | ||
| Full Title: A pilot trial of noninvasive assessment of methotrexate hepatotoxicity in the course of pharmacokinetically guided pharmacotherapy of psoriasis with methotrexate and folic acid | ||
| Medical condition: moderate-severe and severe plaque psoriasis | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: CZ (Completed) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2013-000572-15 | Sponsor Protocol Number: EGF117268 | Start Date*: 2013-07-01 |
| Sponsor Name:GlaxoSmithKline Research & Development Ltd | ||
| Full Title: Investigation of immune mechanisms relating to lapatinib associated hepatotoxicity: ex vivo T cell biology investigation relating to lapatinib induced liver adverse events using PBMCs from patie... | ||
| Medical condition: The subjects participated in the EGF105485 study, a randomized, placebo-controlled study of lapatinib in HER2-positive early-stage breast cancer. During participation in this study, subjects had b... | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Female | |
| Trial protocol: DK (Completed) ES (Ongoing) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2005-004321-26 | Sponsor Protocol Number: 1100.1452 | Start Date*: 2006-02-17 |
| Sponsor Name:Boehringer Ingelheim Pharma GmbH & Co. KG | ||
| Full Title: A Case-Control Toxicogenomics Study to identify Unique Genetic Polymorphisms in Patients who have experienced Symptomatic Hepatotoxicity or Severe Cutaneous Toxicity within the First 8 weeks of Nev... | ||
| Medical condition: The patient population for this study will be comprised of patients with HIV-1 infection who have taken or are currently taking nevirapine and who have (cases) or have not (controls) experienced sy... | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: DE (Completed) GB (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2017-002724-25 | Sponsor Protocol Number: 08-2018-07-31 | Start Date*: 2017-11-16 | |||||||||||
| Sponsor Name:Helle Holst | |||||||||||||
| Full Title: Intravenous and oral paracetamol in neonates: safety and ethanol-drug interactions – the PARASHUTE Trial | |||||||||||||
| Medical condition: Liver toxicity following prolonged administration of i.v. or oral paracetamol | |||||||||||||
|
|||||||||||||
| Population Age: Preterm newborn infants, Newborns, Under 18 | Gender: Male, Female | ||||||||||||
| Trial protocol: DK (Prematurely Ended) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2005-002160-28 | Sponsor Protocol Number: hepatology_MT_2005-05 | Start Date*: 2005-09-23 |
| Sponsor Name:Medical University Graz,Department of Internal Medicine, Division of Gastroenterology and Hepatology | ||
| Full Title: Safety and efficacy of long-term treatment with atorvastatin in patients with primary biliary cirrhosis | ||
| Medical condition: Reduction of cardiovascular risk may become key for the management of PBC. Therefore information on safety and efficacy (lipid-lowering effects) of statins in chronic cholestatic disorders is essen... | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: AT (Completed) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2009-013456-76 | Sponsor Protocol Number: roofthooft/paracetamol | Start Date*: 2010-04-22 |
| Sponsor Name: | ||
| Full Title: Pharmakokinetics and Pharmacodynamics of Acetaminophen( paracetamol i.v) in Neonates | ||
| Medical condition: We want to determine the optimal loading dose of intravenous Acetaminophen in neonates of different gestational age subgroups. To this effect a loading dose of 10mg/kg, 15mg/kg or 20mg/kg Acetam... | ||
| Disease: | ||
| Population Age: Preterm newborn infants, Newborns, Under 18 | Gender: Male, Female | |
| Trial protocol: NL (Ongoing) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2009-015904-24 | Sponsor Protocol Number: UKB-2009-MED-I-JKR-01 | Start Date*: 2010-10-20 |
| Sponsor Name:Rheinische Friedrich-Wilhelms-Universität Bonn | ||
| Full Title: An open, prospective study to compare the safety and efficacy of raltegravir vs. atazanavir / ritonavir, both in combination with tenofovir DF and emtricitabine, in the treatment of HIV-infection i... | ||
| Medical condition: HIV disease | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: DE (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2009-017148-15 | Sponsor Protocol Number: CCOX189A2483 | Start Date*: 2010-04-12 |
| Sponsor Name:NOVARTIS FARMA | ||
| Full Title: A retrospective pharmacogenetic analysis of patients with elevated liver enzymes (Hy s law cases or AST/ALT > 10x ULN) in clinical studies CCOX189A0117, CCOX189A2332, CCOX189A2369, CCOX189A0126,... | ||
| Medical condition: patients with elevated liver enzymes (Hy s law cases or AST/ALT > 10x ULN | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: IT (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2016-003409-33 | Sponsor Protocol Number: AllopurinolALL3.1 | Start Date*: 2016-12-09 |
| Sponsor Name:Västra Götaland Regionen | ||
| Full Title: Optimizing 6-mercaptopurine therapy in pediatric acute lymphoblastic leukemia by using allopurinol. Clinical study in children 1-19 years on maintenance therapy for acute lymphoblastic leukemia. | ||
| Medical condition: Acute lymphoblastic leukemia diagnosed at age 0-18 in children | ||
| Disease: | ||
| Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | |
| Trial protocol: SE (Completed) FI (Completed) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2022-000632-27 | Sponsor Protocol Number: PORT-01 | Start Date*: 2022-08-03 |
| Sponsor Name:Radboud University Medical Center | ||
| Full Title: Pragmatic trial on the safety and tolerability of an optimized dose of rifampicin in tuberculosis patients | ||
| Medical condition: Tuberculosis | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: NL (Trial now transitioned) DK (Trial now transitioned) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2009-017800-10 | Sponsor Protocol Number: CZB/4/722 | Start Date*: 2010-04-01 | ||||||||||||||||
| Sponsor Name:NHS Lothian [...] | ||||||||||||||||||
| Full Title: Scottish and Newcastle Anti-emetic Pre-treatment for Paracetamol Poisoning study (SNAP) | ||||||||||||||||||
| Medical condition: Paracetamol overdose | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |||||||||||||||||
| Trial protocol: GB (Completed) | ||||||||||||||||||
| Trial results: View results | ||||||||||||||||||
| EudraCT Number: 2011-001288-32 | Sponsor Protocol Number: I3CPh1-FSM-01.11 | Start Date*: 2011-04-18 | |||||||||||
| Sponsor Name:FONDAZIONE SALVATORE MAUGERI - CLINICA DEL LAVORO E DELLA RIABILITAZIONE | |||||||||||||
| Full Title: A Pilot Study to Evaluate the Safety and Tolerability of the combination ot Trabectidin and Indole-3-Carbinol in refractory ER-positive metastatic breast cancer | |||||||||||||
| Medical condition: Refractory ER-positive metastatic breast cancer | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Female | ||||||||||||
| Trial protocol: IT (Completed) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2006-001899-20 | Sponsor Protocol Number: DAR-311-E | Start Date*: 2007-01-16 | |||||||||||
| Sponsor Name:Gilead Sciences Inc. | |||||||||||||
| Full Title: DORADO-EX – A Dose-Blinded, Long-Term Safety Extension Study to the Phase 3 DORADO Study (Protocol DAR-311) of Darusentan in Resistant Hypertension A Dose-Blinded, Long-Term Safety Extension Study... | |||||||||||||
| Medical condition: Resistant hypertension | |||||||||||||
|
|||||||||||||
| Population Age: | Gender: Male, Female | ||||||||||||
| Trial protocol: GB (Completed) DK (Completed) SE (Prematurely Ended) FR (Completed) DE (Prematurely Ended) IT (Prematurely Ended) ES (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2010-023437-30 | Sponsor Protocol Number: A7281006 | Start Date*: 2011-09-29 | |||||||||||
| Sponsor Name:Pfizer Inc., 235 East 42nd Street, New York, NY 10017 | |||||||||||||
| Full Title: A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF-00547659 IN SUBJECTS WITH CROHN’S DISEASE(OPERA) | |||||||||||||
| Medical condition: Crohn's Disease | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: SK (Completed) BE (Completed) SE (Completed) AT (Completed) DE (Completed) PT (Prematurely Ended) NO (Completed) NL (Completed) ES (Completed) PL (Completed) BG (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2022-001656-41 | Sponsor Protocol Number: TCeD21 | Start Date*: 2022-12-07 |
| Sponsor Name:Topas Therapeutics GmbH | ||
| Full Title: A double-blind, randomized, placebo-controlled, phase 2a study to evaluate the safety, tolerability, and pharmacodynamic (PD) effects of two infusions of escalating doses of TPM502 in adults diagno... | ||
| Medical condition: Coeliac disease | ||
| Disease: | ||
| Population Age: Adults | Gender: Male, Female | |
| Trial protocol: NO (Completed) FI (Completed) DE (Completed) NL (Completed) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2020-002106-68 | Sponsor Protocol Number: CTU/2020/354 | Start Date*: 2020-07-16 | |||||||||||
| Sponsor Name:University College London Comprehensive Clinical Trial Unit | |||||||||||||
| Full Title: Favipiravir, lopinavir/ritonavir or combination therapy: a randomised, double blind, 2x2 factorial placebo-controlled trial of early antiviral therapy in COVID-19 | |||||||||||||
| Medical condition: SARS-CoV-2 (Corona virus) infection | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2020-003413-35 | Sponsor Protocol Number: WN42349 | Start Date*: 2020-12-07 | |||||||||||
| Sponsor Name:F. Hoffmann-La Roche Ltd | |||||||||||||
| Full Title: A MULTICENTER, SINGLE ARM, OPEN-LABEL STUDY TO EVALUATE THE LONG-TERM SAFETY AND EFFICACY OF SATRALIZUMAB IN PATIENTS WITH NEUROMYELITIS OPTICA SPECTRUM DISORDER (NMOSD) | |||||||||||||
| Medical condition: Neuromyelitis Optic Spectrum Disorder | |||||||||||||
|
|||||||||||||
| Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: GB (GB - no longer in EU/EEA) DE (Completed) HU (Completed) BG (Completed) PL (Completed) IT (Completed) HR (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2005-005023-33 | Sponsor Protocol Number: 1182.99 | Start Date*: 2007-03-15 | |||||||||||
| Sponsor Name:Boehringer Ingelheim France SAS | |||||||||||||
| Full Title: Safety and efficacy study of TPV boosted with low dose ritonavir (TPV/r) 500 mg/200 mg BID in antiretroviral treatment experienced HIV positive patients with HCV or HBV co-infection, with a pilot e... | |||||||||||||
| Medical condition: Treatment with three-class (NRTI, NNRTI, and PI) experienced HIV positive patients with HCV or HBV co-infection, with a minimum of 3-months duration for each class and have documented resistance to... | |||||||||||||
|
|||||||||||||
| Population Age: Adults | Gender: Male, Female | ||||||||||||
| Trial protocol: FR (Completed) PT (Prematurely Ended) ES (Completed) DE (Prematurely Ended) IT (Prematurely Ended) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2019-001585-15 | Sponsor Protocol Number: 2018-01671 | Start Date*: 2020-01-30 |
| Sponsor Name:Centre Hospitalier Universitaire Vaudois | ||
| Full Title: PTX3 genetically stratified randomized double-blinded allocation eventdriven clinical trial for antifungal prophylaxis in patients with acute myeloid leukemia | ||
| Medical condition: Patients with acute myeloid leukemia (AML) or myelodysplastic syndrome in transformation (MDSit) who receive antifungal profylaxis during their treatment with an intensive chemotherapy regimen, inc... | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: BE (Trial now transitioned) FR (Trial now transitioned) | ||
| Trial results: (No results available) | ||
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
| Download Options: | |
|---|---|
| Number of Trials to download: | |
| Download Content: | |
| Download Format: | |
| Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. | |
Query did not match any studies.
